WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Blaine McKee, Ph.D. has been appointed Executive Vice President and Chief Business Officer.
“As ImmunoGen continues to evolve, we look to complement our existing team with outside talent with experience to accelerate our transition to a fully-integrated biotechnology company delivering innovative products to improve outcomes for cancer patients,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “Blaine’s successful track record in leading strategy, corporate development, and commercial assessment functions for premier companies will be invaluable as we advance towards our goal of bringing mirvetuximab soravtansine to market in 2020.”
Dr. McKee brings 25 years of experience in building biotechnology companies and has extensive strategic, transactional, and market access expertise. He joins ImmunoGen from Shire plc, where he served as Head of Corporate Development, leading corporate strategy, M&A, due diligence, commercial assessment, and alliance management functions. Prior to joining Shire, Dr. McKee was Executive Vice President and Chief Business Officer at 480 Biomedical, a venture capital-backed medical device company. Before joining 480 Biomedical, he held a number of positions of increasing responsibility at Genzyme over a 15-year tenure, most recently serving as Senior Vice President of Strategic Development for the Oncology, Transplant, and Multiple Sclerosis divisions.
Dr. McKee currently serves on the Board of BioStage, Inc. and served for many years on the Board of the New York Pharma Forum. He received a Bachelor of Science in Chemistry from Colorado State University, a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT), and an MBA in Finance from the MIT Sloan School of Management.
“I am excited to join ImmunoGen during this transformational time,” said Dr. McKee. “The Company is well-positioned to realize its full potential by building on its leadership in ADCs with continued innovation in oncology. I look forward to working with the talented team at ImmunoGen to bring novel ADCs to market and make a meaningful difference in the lives of cancer patients.”
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics using
its proprietary ADC technology. The Company’s lead product candidate,
mirvetuximab soravtansine, is in the FORWARD I Phase 3 trial for
FRα-positive platinum-resistant ovarian cancer, and is in the FORWARD II
Phase 1b/2 trial in combination regimens for earlier-stage disease.
ImmunoGen has three additional clinical-stage product candidates, two of
which are being developed in collaboration with Jazz Pharmaceuticals.
ImmunoGen's ADC technology is also used in Roche's marketed product,
Kadcyla®, and in programs in development by Amgen, Bayer,
Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi, and Takeda. More
information about the Company can be found at www.immunogen.com.
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Transition Report on Form 10-K for the fiscal year ended December 31, 2017 and other reports filed with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180425005085/en/
